Archive for the
‘2023’ Category

Ghent, Belgium – September 12, 2023 – Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), today announced the appointment of Stephen Dowd, PhD, MBA, to its executive team as Chief Business Officer (CBO). “We are thrilled to welcome Stephen to Confo and believe his considerable experience will make him an […]

12. September 2023

|

by: confo

|

Categories: 2023, Allgemein

Ghent, Belgium – August 29, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the appointment of Dieter Weinand as Independent Chairman of its Board of Directors. Mr. Weinand brings with him a wealth of experience with more than 35 years in the pharmaceutical industry and over 25 years as the […]

29. August 2023

|

by: confo

|

Categories: 2023, Allgemein

Collaboration to make use of Confo’s unique suite of ConfoBody®-enabled antibody discovery technologies on two GPCR targets Confo to receive upfront and milestone payments Tiered royalties payable to Confo on net sales from resulting products Ghent, Belgium – June 15, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors […]

15. June 2023

|

by: confo

|

Categories: 2023, Allgemein

Collaboration to make use of Confo’s unique suite of ConfoBody®-enabled technologies for fragment- and structure-based drug design Confo to receive upfront and milestone payments totaling EUR 168M Tiered royalties payable to Confo on net sales from resulting products Ghent, Belgium – March 30, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting […]

30. March 2023

|

by: confo

|

Categories: 2023, Allgemein

Confo to receive upfront and milestone payments totaling $630M Company is eligible for up to $590M in additional milestones if Lilly proceeds with a second product candidate Tiered royalties payable to Confo on net sales Confo to have a co-investment option Ghent, Belgium – March 2, 2023 – Confo Therapeutics, a leader in the discovery […]

2. March 2023

|

by: confo

|

Categories: 2023, Allgemein

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close